The way to prepare the pharmaceutical business for an investment deal, which documents to prepare and how long the process may take, said Alexander Lobakov, Managing Partner of the investment company Novus Capital
A consortium of investors, including the Russian Private Equity Fund (RPEF), the Russian-Chinese Investment Fund (RCIF) and a group of Middle Eastern funds, will obtain 28% in the pharmaceutical enterprise Obolenskoe. The cost of the transaction will exceed 4 billion rubles.
The results of the nineteenth season of the All-Russian Open Competition of Pharmaceutical Industry Professionals “Platinum Ounce” were summed up at the award ceremony.
On May 14, in terms of the 25th Russian Pharmaceutical Forum, a round table “M & A: trends, events, prospects” will be held. During the discussion insights in the most significant M & A deals closed in 2018 will be disclosed.
The share of domestic pharmaceutical companies in the Russian market reached 30 percent, as the study of the investment company Novus Capital shows. The total volume of the pharmaceutical market reached 930 billion rubles in 2018.
Since 2016 Ukrainian company Kreoma Pharm has filed lawsuits against Russian company TNK Silma, accusing it of violating patent and copyright rights for pharmaceutical product Enterosgel, reported the press release sent to Izvestia.
The Russian economy is being diversified, many industries are localized
In general the nominal quantity of investors in Russia has not decreased, but the real number of transactions dropped last year. This is primarily due to the economic situation in Russia, particularly in relation to its perspective, said to a REGNUM correspondent Alexander Lobakov, managing partner of Novus Capital.
The Fund RBV Capital, created with the participation of RVC and R-Pharm, will receive up to 10% of the sale of the Irish Allergan to the American company Bonti. The initial payment will amount to $ 195 million, under certain conditions additional payments may follow.
BIOCAD and SPH Agree to Build a Drug Substance Manufacturing Facility in China
SAINT PETERSBURG, Russia--(BUSINESS WIRE)--This year at the Eastern Economic Forum in Vladivostok, BioCad and Shanghai Pharmaceutical Holding entered into a Memorandum of Understanding to create two joint ventures for production, clinical development, registration, and marketing of several high-cost medicines based on monoclonal antibodies in the People's Republic of China.
© All rights reserved, 2015-2019